- Pfizer pays an annualized dividend of $1.72 per share, producing a 6.88% forward yield at $25.01.
- Trailing four-quarter free cash flow of roughly $11 billion exceeds estimated annual dividend payments of $9.8 billion.
- Weak dividend growth and reliance on pipeline execution leave PFE dividends exposed to meaningful risks.
Current Income Snapshot
At $25.01, Pfizer (NYSE: PFE) pays a quarterly dividend of $0.43 per share, or $1.72 annualized. That produces a forward yield of 6.88%, far above the S&P 500’s roughly 1% yield.
The most recent ex-dividend date was July 24, with payment scheduled for September 1. Pfizer has kept the quarterly payout unchanged, while dividend growth has been modest at 0.6% over one year and 1.8% annualized over three years.
For income investors, PFE dividends are primarily a high-current-yield holding, not a dependable dividend-growth compounder.
Cash Flow Still Covers the Payout
Cash generation, rather than reported net income, is the key test after Pfizer’s large impairment charges. Pfizer generated roughly $11 billion in trailing four-quarter free cash flow, exceeding its dividend requirement.
The company expects about $9.8 billion in annual dividend payments, leaving a cushion of approximately $1.2 billion. That margin is positive but not wide.
A weak quarter, higher restructuring spending, debt reduction, or another major acquisition could tighten coverage quickly. The reported earnings decline is less alarming because the recent $4.3 billion intangible-asset impairment was non-cash.
Business Moves Beyond COVID
Newer medicines must replace lost pandemic revenue and future patent expirations. COVID products continue to decline sharply, but Pfizer’s non-COVID portfolio is stabilizing.
The company delivered 5% operational growth excluding Comirnaty and Paxlovid, supported by products including Eliquis, Padcev, Lorbrena, and Vyndaqel. Management also raised overall revenue guidance while planning another $2.5 billion in cost savings for 2027 through 2029.
Those measures could support future free cash flow, although drug launches, clinical results, and acquisition integration remain decisive.
Insider Buying Adds a Small Positive Signal
Management’s recent share purchases show confidence, but they do not remove the fundamental risks. Chief Executive Albert Bourla bought 38,000 Pfizer shares at $26.34 on August 12, an investment of about $1 million.
PFE’s stock price sits near the lower half of its $23.40 to $28.75 52-week range, helping explain why its yield is elevated. However, Pfizer’s five-year share-price performance has lagged badly despite large dividend payments.
Dividend Investor Takeaway
The current $1.72 Pfizer dividend appears sustainable on present free cash flow, and the nearly 7% yield is compelling. But coverage is only modest, dividend growth is weak, and long-term safety depends on pipeline success, cost cuts, debt discipline, and replacement of COVID-era sales.
PFE can fit a diversified income portfolio, but it is best treated as a monitored high-yield position rather than a buy-and-forget dividend growth stock.
